Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Out Of The Ashes: Roche’s Dalcetrapib Data Suggest Still Hope For CETP Inhibitor Class

Executive Summary

Experts see various reasons why Roche’s HDL-raising drug may have failed to demonstrate benefit in the dal-OUTCOMES study, including insufficient potency resulting from only partial CETP inhibition. Final word on the class’ fate likely will not be written until outcomes studies by Merck and Lilly report out in several years.

You may also be interested in...



Big REVEAL: Merck's Anacetrapib Surprises With Success, But What Next?

The positive top-line results for Merck & Co's cardiovascular outcomes trial for its CETP inhibitor anacetrapib may not be enough to de-risk the class, and questions remain about the level of clinical benefit and the regulatory options.

Who Suffers From Lilly's Evacetrapib Failure?

Lilly hits a late-stage snag that causes worries about its pipeline potential and has repercussions for several other companies working in the cholesterol space.

Dezima Pharma Raises $18.6 Million For Next-Generation CETP Inhibitor

Dutch start-up Dezima Pharma raises $18.6 million in Series A funding and government loans to move a next-generation CETP inhibitor to Phase III.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS054888

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel